Daniel J Drucker Selected Research

gastric inhibitory polypeptide receptor

3/2024	Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
11/2022	Genetic disruption of the Gipr in Apoe-/- mice promotes atherosclerosis.
1/2022	GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue.
1/2021	The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
10/2019	Physiological roles of the GIP receptor in murine brown adipose tissue.
1/2019	GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9.
1/2018	Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction.
1/2012	Gipr is essential for adrenocortical steroidogenesis; however, corticosterone deficiency does not mediate the favorable metabolic phenotype of Gipr(-/-) mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel J Drucker Research Topics

Disease

66	Type 2 Diabetes Mellitus (MODY) 12/2023 - 01/2002
46	Body Weight (Weight, Body) 03/2024 - 03/2003
44	Obesity 03/2024 - 05/2006
29	Inflammation (Inflammations) 12/2023 - 05/2006
25	Insulin Resistance 01/2022 - 10/2003
21	Weight Loss (Weight Reduction) 01/2023 - 11/2006
12	Hyperglycemia 11/2018 - 02/2003
10	Weight Gain 11/2022 - 11/2006
10	Hypoglycemia (Reactive Hypoglycemia) 04/2019 - 10/2003
9	Myocardial Infarction 12/2022 - 04/2009
9	Neoplasms (Cancer) 04/2019 - 07/2002
8	Glucose Intolerance 01/2018 - 02/2004
7	Atherosclerosis 11/2022 - 01/2013
6	Fibrosis (Cirrhosis) 01/2024 - 01/2013
6	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2021 - 11/2007
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 05/2014
5	Ischemia 10/2017 - 05/2008
5	Hyperplasia 04/2013 - 04/2010
4	Infarction (Infarctions) 12/2022 - 04/2009
4	Diabetes Mellitus 08/2017 - 01/2002
3	Nausea 01/2021 - 01/2002
3	Albuminuria 01/2020 - 03/2014
3	Hypertension (High Blood Pressure) 01/2020 - 10/2016
3	Short Bowel Syndrome 04/2019 - 01/2014
3	medullary Thyroid cancer 01/2018 - 07/2011
3	Pancreatitis 01/2018 - 09/2009
3	Anorexia 04/2013 - 01/2005
2	Chronic Renal Insufficiency 01/2024 - 12/2023
2	Diabetic Nephropathies (Diabetic Nephropathy) 12/2023 - 03/2014
2	Fatty Liver 12/2023 - 10/2019
2	Liver Diseases (Liver Disease) 12/2023 - 01/2020
2	Infections 01/2023 - 12/2020
2	Stroke (Strokes) 11/2021 - 01/2018
2	Vomiting 01/2021 - 01/2002
2	Metabolic Diseases (Metabolic Disease) 01/2021 - 01/2017
2	Intestinal Failure 01/2020 - 01/2020
2	Cardiomegaly (Heart Hypertrophy) 01/2020 - 03/2016
2	Vascular System Injuries 01/2018 - 12/2016
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018 - 05/2006
2	Heart Diseases (Heart Disease) 11/2017 - 07/2009
2	Hypertrophy 02/2015 - 01/2013

Drug/Important Bio-Agent (IBA)

70	Glucose (Dextrose)FDA LinkGeneric 03/2024 - 01/2002
65	Glucagon-Like Peptide 1 (GLP 1)IBA 03/2024 - 01/2002
38	Glucagon-Like Peptide-1 ReceptorIBA 12/2023 - 09/2005
27	IncretinsIBA 10/2023 - 01/2002
26	Glucagon (Glukagon)FDA Link 07/2023 - 10/2003
19	Liraglutide FDA Link 12/2023 - 11/2006
18	Insulin (Novolin)FDA Link 01/2022 - 10/2003
16	Peptides (Polypeptides)IBA 03/2024 - 01/2002
13	Glucagon-Like Peptide-1 Receptor AgonistsIBA 12/2023 - 01/2002
13	Hormones (Hormone)IBA 12/2023 - 07/2002
13	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2018 - 01/2002
11	Exenatide (Byetta)FDA Link 03/2015 - 01/2003
9	Glucagon Receptors (Glucagon Receptor)IBA 01/2024 - 10/2005
8	gastric inhibitory polypeptide receptorIBA 03/2024 - 01/2012
8	LipidsIBA 01/2024 - 06/2010
8	Blood Glucose (Blood Sugar)IBA 04/2013 - 01/2002
7	Sitagliptin Phosphate (Januvia)FDA Link 01/2020 - 11/2006
6	LeptinIBA 03/2024 - 01/2008
6	semaglutideIBA 01/2022 - 08/2017
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2008
6	Glucagon-Like Peptides (Enteroglucagon)IBA 01/2020 - 07/2002
5	fibroblast growth factor 21IBA 01/2023 - 01/2016
5	Messenger RNA (mRNA)IBA 11/2022 - 10/2003
5	EnzymesIBA 01/2020 - 05/2007
5	Metformin (Glucophage)FDA LinkGeneric 01/2020 - 01/2002
5	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 10/2017 - 01/2002
4	SugarsIBA 01/2023 - 04/2013
4	Triglycerides (Triacylglycerol)IBA 01/2021 - 04/2008
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2018
4	Proglucagon (Glucagon Precursors)IBA 04/2019 - 07/2002
4	Streptozocin (Streptozotocin)FDA Link 11/2015 - 11/2008
3	Lipoproteins (Lipoprotein)IBA 12/2023 - 09/2009
3	Appetite Depressants (Anorectics)IBA 10/2023 - 07/2013
3	CarbohydratesIBA 01/2023 - 02/2008
3	Interleukin-6 (Interleukin 6)IBA 12/2022 - 10/2011
3	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2020 - 02/2008
3	CytokinesIBA 10/2019 - 01/2003
3	Therapeutic UsesIBA 10/2019 - 02/2002
3	Hypoglycemic Agents (Hypoglycemics)IBA 01/2018 - 09/2009
3	Dextran SulfateIBA 06/2012 - 02/2002
3	Glucagon-Like Peptide-2 ReceptorIBA 09/2010 - 10/2005
2	Dietary Carbohydrates (Carbohydrate, Dietary)IBA 01/2023 - 01/2023
2	Peptide Hydrolases (Proteases)FDA Link 01/2023 - 01/2002
2	LinagliptinIBA 01/2023 - 10/2016
2	Apolipoproteins E (ApoE)IBA 11/2022 - 01/2013
2	LipopolysaccharidesIBA 10/2022 - 02/2014
2	teduglutideIBA 04/2019 - 02/2015
2	Peptide Hormones (Polypeptide Hormones)IBA 12/2016 - 07/2013
2	SodiumIBA 10/2016 - 01/2015
2	CholesterolIBA 10/2016 - 01/2015
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2016 - 08/2014
2	salicylhydroxamic acid (SHAM)IBA 03/2014 - 02/2003

Therapy/Procedure

31	Therapeutics 12/2023 - 01/2002
6	Glycemic Control 01/2021 - 06/2010
5	Bariatric Surgery 01/2022 - 07/2013
3	Drug Therapy (Chemotherapy) 01/2022 - 02/2002
3	Injections 01/2021 - 11/2006
2	Parenteral Nutrition 02/2015 - 01/2014
2	Ligation 02/2015 - 04/2010